Tempest Therapeutics Inc (NAS:TPST)
$ 1.42 -0.04 (-2.74%) Market Cap: 35.80 Mil Enterprise Value: 24.93 Mil PE Ratio: 0 PB Ratio: 2.05 GF Score: 36/100

Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 11:00AM GMT
Release Date Price: $0.4384 (+6.95%)
Steve Bersey
H.C. Wainwright & Co., LLC - Analyst

Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve Bersey. I'm an equity research associate here at H.C. Wainwright.

So now, I'd like to welcome Tempest Therapeutics.

Sam Whiting
Tempest Therapeutics, Inc. - Chief Medical Officer and Head of R&D

Sam Whiting, Chief Medical Officer at Tempest. Tempest would like to thank H.C. Wainwright for the opportunity to present at the 25th Annual Investment Conference. Tempest is a publicly traded company, and I will be making forward-looking statements. Please see our most recent SEC filings.

Tempest Therapeutics is a small but experienced biotech company that exemplifies a diversified opportunity in the oncology space. We have multiple programs, spanning from randomized Phase 2 data in a globally relevant indication in the first-line setting down to novel preclinical programs that are still undisclosed in order to maintain our development advantage.

Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot